BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...in a series A round led by Versant Ventures...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...part of what the company is working on.Of syndicates and SoftbankThe series C round saw Versant Ventures...
...Logos Capital, which co-led the deal with fellow new investor Boxer Capital of Tavistock Group. Versant...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...in an IPO through the sale of 8 million shares at $13.$80M series C for Versant-grown...
...Suvretta Capital and Red Tree Venture Capital. All the company’s existing shareholders, including founding investor Versant Ventures...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...biotechs, and VC firms 5AM Ventures and Versant Ventures...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...start-ups, including cell therapy company Lyell Immunopharma Inc., Versant-backed...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...Alexandria Venture Investments and others, including series A investors venBio Partners, Versant Ventures and Samsara Bio Capital.Versant’s...
...Jerel Davis said the firm scouted radiotherapy opportunities for three years before investing in RayzeBio Inc. Versant...
BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...milestones. He was also a partner at Versant Ventures...
BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

...at Versant Ventures and CEO of Blueline Bioscience, Versant’s...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...A round co-led by venBio Partners and Versant Ventures...
...have not yet been addressed with radiopharmaceuticals. Versant’s...
...employees: 10Funds raised: $45 millionInvestors: venBio Partners, Versant Ventures...
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...a £29 million ($40.9 million) series B round in 2018. Investors included Epidarex Capital, IP Group, Versant Ventures...
Items per page:
1 - 10 of 585
BioCentury | Feb 26, 2021
Product Development

The dark of COVID-19 brings promise to Germany’s biotech scene

...in a series A round led by Versant Ventures...
BioCentury | Feb 25, 2021
Finance

$135M series C buys Vividion flexibility to explore broad pipeline

...part of what the company is working on.Of syndicates and SoftbankThe series C round saw Versant Ventures...
...Logos Capital, which co-led the deal with fellow new investor Boxer Capital of Tavistock Group. Versant...
BioCentury | Feb 12, 2021
Deals

Feb. 11 Quick Takes: First day pop for Bioventus; plus venture rounds for Pipeline, Immunai, Sanofi, i2O, AZ’s trimmings, Truveta

...in an IPO through the sale of 8 million shares at $13.$80M series C for Versant-grown...
...Suvretta Capital and Red Tree Venture Capital. All the company’s existing shareholders, including founding investor Versant Ventures...
BioCentury | Jan 1, 2021
Product Development

Not done yet. The COVID R&D Alliance has plenty on its plate for 2021

...biotechs, and VC firms 5AM Ventures and Versant Ventures...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...start-ups, including cell therapy company Lyell Immunopharma Inc., Versant-backed...
BioCentury | Dec 12, 2020
Finance

RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

...Alexandria Venture Investments and others, including series A investors venBio Partners, Versant Ventures and Samsara Bio Capital.Versant’s...
...Jerel Davis said the firm scouted radiotherapy opportunities for three years before investing in RayzeBio Inc. Versant...
BioCentury | Dec 4, 2020
Finance

NASDAQ IPOs near $20B raised in ‘20, as Kinnate prices deal

...milestones. He was also a partner at Versant Ventures...
BioCentury | Dec 1, 2020
Emerging Company Profile

Spotlight: solving CRISPR’s delivery challenges with RNPs

...at Versant Ventures and CEO of Blueline Bioscience, Versant’s...
BioCentury | Oct 15, 2020
Emerging Company Profile

RayzeBio pulling together radiotherapy platform with $45 million

...A round co-led by venBio Partners and Versant Ventures...
...have not yet been addressed with radiopharmaceuticals. Versant’s...
...employees: 10Funds raised: $45 millionInvestors: venBio Partners, Versant Ventures...
BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...a £29 million ($40.9 million) series B round in 2018. Investors included Epidarex Capital, IP Group, Versant Ventures...
Items per page:
1 - 10 of 585